Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Inclusion Criteria: * Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma. * Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid (CSF) cytology examination or vitrectomy. * Disease exclusively localized into the central nervous system, CSF, cranial nerves or eyes. * At least one measurable lesion. * Previously untreated patients (previous or ongoing steroid therapy admitted). * Age 18-65 years (with ECOG Performance Status 0-3) or 66-70 (with ECOG Performance Status 0-2). * Adequate bone marrow, renal, cardiac, and hepatic function. * Sexually active patients of childbearing potential agreeing in implementing adequate contraceptive measures during study participation. * Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. * Patient-signed informed consent obtained before registration. Exclusion Criteria: * Patients with lymphomatous lesions outside the CNS. * Patients with a previous non-Hodgkin lymphoma at any time. * Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least from 5 years. * HBsAg and HCV positivity. * HIV infection, previous organ transplantation or other clinically evident form of immunodeficiency. * Concurrent treatment with other experimental drugs. * Concurrent Pregnancy or lactation. * Patients not agreeing to take adequate contraceptive measures during the study. * Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease).